Polymeric Lipid Hybrid Nanoparticles as a Delivery System Enhance the Antitumor Effect of Emodin in Vitro and in Vivo

Liu, Hui; Zhuang, Yong; Wang, Panpan; Zou, Tengteng; Lan, Meng; Li, Lihong; Liu, Fengjie; Cai, Tiange; Cai, Yu

doi:10.1016/j.xphs.2021.04.006

Cited by 13 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The average particle size of the E-PLNs was 122.7 ± 1.79 nm, and the encapsulation rate was 72.8%. Compared with free emodin, E-PLNs showed greater toxicity towards MCF-7 cells by promoting emodin uptake and inducing apoptosis [53]. Emodin and emodin-containing scaffolds were also shown as cytotoxic toward the GILM2 human BC cell line obtained from lung metastasis [24].…”

Section: Anticancer Activity Of 18-dihydroanthraquinone Derivatives I...mentioning

confidence: 97%

Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer

Okon,

Gaweł-Bęben,

Jarzab

et al. 2023

IJMS

View full text Add to dashboard Cite

Breast cancer (BC) is the most common malignancy among women worldwide. In recent years, significant progress has been made in BC therapy. However, serious side effects resulting from the use of standard chemotherapeutic drugs, as well as the phenomenon of multidrug resistance (MDR), limit the effectiveness of approved therapies. Advanced research in the BC area is necessary to create more effective and safer forms of therapy to improve the outlook for individuals diagnosed with this aggressive neoplasm. For decades, plants and natural products with anticancer properties have been successfully utilized in treating various medical conditions. Anthraquinone derivatives are tricyclic secondary metabolites of natural origin that have been identified in plants, lichens, and fungi. They represent a few botanical families, e.g., Rhamnaceae, Rubiaceae, Fabaceae, Polygonaceae, and others. The review comprehensively covers and analyzes the most recent advances in the anticancer activity of 1,8-dihydroanthraquinone derivatives (emodin, aloe-emodin, hypericin, chrysophanol, rhein, and physcion) applied both individually, or in combination with other chemotherapeutic agents, in in vitro and in vivo BC models. The application of nanoparticles for in vitro and in vivo evidence in the context of 1,8-dihydroanthraquinone derivatives was also described.

show abstract

Section: Anticancer Activity Of 18-dihydroanthraquinone Derivatives I...mentioning

confidence: 97%

Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer

Okon,

Gaweł-Bęben,

Jarzab

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…The average particle size of the E-PLNs was 122.7±1.79 nm, and the encapsulation rate was 72.8%. Compared with free emodin E-PLNs showed greater toxicity towards MCF-7 cells by promoting emodin uptake and inducing apoptosis [52]. Emodin and emodin-containing scaffolds were also shown as cytotoxic toward the GILM2 human BC cell line obtained from lung metastasis [24].…”

Section: Emodinmentioning

confidence: 97%

Therapeutic Potential of Anthracene Derivatives for Breast Cancer

Okon,

Gawel-Beben,

Jarzab

et al. 2023

Preprint

View full text Add to dashboard Cite

Breast cancer (BC) is the most common malignancy among women worldwide. In recent years, significant progress has been made in BC therapy. However, serious side effects resulting from the use of standard chemotherapeutic drugs, as well as the phenomenon of multidrug resistance (MDR), limit the effectiveness of approved therapies. Advanced research in the BC area is necessary to create more effective and safer forms of therapy to improve the outlook for individuals diagnosed with this aggressive neoplasm. For decades, plants and natural products with anti-cancer properties have been successfully utilized in treating various medical conditions. Anthracene derivatives are tricyclic secondary metabolites of natural origin that have been identified in plants, lichens, and fungi. They represent a few botanical families, e.g., Rhamnaceae, Rubia-ceae, Fabaceae, Polygonaceae, and others. The review comprehensively covers and analyzes the most recent advances in the anticancer activity of anthracene derivatives (emodin, aloe-emodin, hypericin, chrysophanol, rhein, and physcion) applied both individually, or in combination with other chemotherapeutic agents in in vitro and in vivo BC models.

show abstract

“…Moreover, delivery strategies based on liposomes with different tissue/cancer-targeting properties were widely used to improve the therapeutic effects of emodin. Specifically, targeted liposomes licensed selectively accumulation of emodin at breast cancer lesions, by targeting and inhibiting vasculogenic mimicry channel on breast cancer cell surface, thus exhibiting a distinct antitumor activity in vivo [ 213 , 214 ]. It was also noteworthy that a magnetically guided liposomal emodin composite was synthesized and enhanced the MCF-7 killing efficiency of hydrophobic free emodin.…”

Section: Modification Of Emodin For Better Therapeutic Potentialmentioning

confidence: 99%

Advances in the study of emodin: an update on pharmacological properties and mechanistic basis

Zheng

et al. 2021

Chin Med

View full text Add to dashboard Cite

Rhei Radix et Rhizoma, also known as rhubarb or Da Huang, has been widely used as a spice and as traditional herbal medicine for centuries, and is currently marketed in China as the principal herbs in various prescriptions, such as Da-Huang-Zhe-Chong pills and Da-Huang-Qing-Wei pills. Emodin, a major bioactive anthraquinone derivative extracted from rhubarb, represents multiple health benefits in the treatment of a host of diseases, such as immune-inflammatory abnormality, tumor progression, bacterial or viral infections, and metabolic syndrome. Emerging evidence has made great strides in clarifying the multi-targeting therapeutic mechanisms underlying the efficacious therapeutic potential of emodin, including anti-inflammatory, immunomodulatory, anti-fibrosis, anti-tumor, anti-viral, anti-bacterial, and anti-diabetic properties. This comprehensive review aims to provide an updated summary of recent developments on these pharmacological efficacies and molecular mechanisms of emodin, with a focus on the underlying molecular targets and signaling networks. We also reviewed recent attempts to improve the pharmacokinetic properties and biological activities of emodin by structural modification and novel material-based targeted delivery. In conclusion, emodin still has great potential to become promising therapeutic options to immune and inflammation abnormality, organ fibrosis, common malignancy, pathogenic bacteria or virus infections, and endocrine disease or disorder. Scientifically addressing concerns regarding the poor bioavailability and vague molecular targets would significantly contribute to the widespread acceptance of rhubarb not only as a dietary supplement in food flavorings and colorings but also as a health-promoting TCM in the coming years.

show abstract

Polymeric Lipid Hybrid Nanoparticles as a Delivery System Enhance the Antitumor Effect of Emodin in Vitro and in Vivo

Cited by 13 publications

References 38 publications

Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer

Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer

Therapeutic Potential of Anthracene Derivatives for Breast Cancer

Advances in the study of emodin: an update on pharmacological properties and mechanistic basis

Contact Info

Product

Resources

About